<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364769">
  <stage>Registered</stage>
  <submitdate>13/08/2013</submitdate>
  <approvaldate>21/08/2013</approvaldate>
  <actrnumber>ACTRN12613000923763</actrnumber>
  <trial_identification>
    <studytitle>Assessing blood levels of ketorolac ( Toradol) injected in around the hip and knee joints in patients undergoing joint replacements</studytitle>
    <scientifictitle>Pharmacokinetic study  of intraarticular and periarticular injection of ketorolac in patients undergoing total hip and knee replacements</scientifictitle>
    <utrn>U1111-1146-6793</utrn>
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Blood levels of analgesics</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Studying the blood levels of ketorolac at 30 minutes, 1,2,4,8,24 hours after intraarticular infiltration during total hip and total knee replacements</interventions>
    <comparator>No control arm</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>serum levels of ketorolac will be analysed using High-performance liquid chromatography (HPLC) at Biochemical laboratory, University of Queensland.</outcome>
      <timepoint>30 mins, 1,2,4,8 and 24 hours post infiltration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Postoperative day 1 routine blood tests: full blood count,  serum urea, creatinine, electrolytes and glomerular filtration rate</outcome>
      <timepoint> first postoperative day</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Should be able to speak and understand English
Should be able to give an informed consent
Patients &gt; 18 yrs of age
Both Male and female patients undergoing Total Hip and Total Knee Replacements
All patients should have normal renal function
Participating patients should have no systemic diseases which include severe heart/lung conditions/bleeding disorders
Not on any medications which could alter renal function
Patients will not receive any further NSAIDs in the first 24 hrs of surgery
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients &lt; 18 yrs of age
Consent not obtained
Impaired renal function 
Patients with severe cardiovascular / lung diseases
Pregnancy/lactation
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>The concentration of Ketorolac will be determined by chromatographic methods that are validated and conducted in accordance with the FDAs guidance for industry on bioanalysis.
The concentration results will be submitted for pharmacokinetic and statistical analysis.
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Random sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>2/09/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>30/09/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <postcode>4032 - Chermside</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr.Usha Gurunathan</primarysponsorname>
    <primarysponsoraddress>The Prince Charles Hospital, Rode Road, Chermside, QLD 4032</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Queensland University of Technology</fundingname>
      <fundingaddress>Musk Ave, Kelvin Grove QLD 4059</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Participating patients will be screened as per the study protocol and will have prior informed consent.  
Ten patients with normal renal function undergoing total knee or hip replacement surgeries are chosen for the study. As per the usual procedure in the hospital, surgeon infiltrates the joint with 100ml of 0.2% ropivacaine with adrenaline along with 30mg ketorolac at the end of surgery. Serial blood samples are taken at 30 mins, 1,2,4,8 and 24 hours post infiltration. Serum concentrations of ketorolac will be analysed using HPLC at Biochemical lab, University of Queensland. The results will be analysed by the research team.
</summary>
    <trialwebsite>NIL</trialwebsite>
    <publication>NIL so far</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>HREC at the Prince Charles Hospital</ethicname>
      <ethicaddress>Rode Road, Chermside, QLD 4032</ethicaddress>
      <ethicapprovaldate>5/11/2012</ethicapprovaldate>
      <hrec>HREC/12/QPCH/147</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Usha Gurunathan</name>
      <address>Department of Anaesthesia &amp; Perfusion services, The Prince Charles Hospital, Rode Road, Chermside, QLD 4032</address>
      <phone> + 61 7 3139 4000</phone>
      <fax />
      <email>usha_gurunathan@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Usha Gurunathan</name>
      <address>Department of Anaesthesia, The Prince Charles Hospital, Rode Road, Chermside, QLD 4032</address>
      <phone> +61 7 3139 4000</phone>
      <fax />
      <email>usha_gurunathan@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Usha Gurunathan</name>
      <address>Department of Anaesthesia, The Prince Charles Hospital, Rode Road, Chermside, QLD 4032</address>
      <phone> +61 7 3139 4000</phone>
      <fax />
      <email>usha_gurunathan@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Usha Gurunathan</name>
      <address>Department of Anaesthesia, The Prince Charles Hospital, Rode Road, Chermside, QLD 4032</address>
      <phone> +61 7 3139 4000</phone>
      <fax />
      <email>usha_gurunathan@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>